Literature DB >> 14606070

Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.

Ru-Lin Cai1, Wei Meng, Hong-Yan Lu, Wen-Yao Lin, Feng Jiang, Fu-Min Shen.   

Abstract

AIM: To explore the mode of inheritance of hepatocellular carcinoma (HCC) in a moderately high-incidence area of East China.
METHODS: A pedigree survey was conducted in 210 families (3315 individuals) ascertained through 210 HCC probands in Haimen, Jiangsu Province. Simple segregation analysis was conducted using SEGRANB software. The probability of ascertainment (pi), segregation ratio (p), and the proportion of sporadic cases (x) were estimated. Complex segregation analysis was performed using the REGTL program of S.A.G.E. Models were fitted on the data of 3212 individuals that allowed for personal HBsAg status and variable age of onset in REGTL program.
RESULTS: The estimate of segregation ratio was 0.191 by SEGRANB. The probability of ascertainment was 0.0266, and the proportion of sporadic cases was 0.465. The results of complex segregation analysis showed that Mendelian autosomal recessive inheritance of a major gene that influenced the age of onset distribution of HCC, provided the best fit to the data. In the best-fitting recessive model, the frequency of the disease allele was 0.11138. HBsAg seropositive status would significantly increase the risk of developing HCC.
CONCLUSION: These results suggest that at least one major gene is involved in the genetic predisposition to develop HCC at an earlier age of onset. The seropositive HBsAg status can significantly increase the risk of developing HCC, which provides strong support for the interaction between genetic and environmental risk factors.

Entities:  

Mesh:

Year:  2003        PMID: 14606070      PMCID: PMC4656515          DOI: 10.3748/wjg.v9.i11.2428

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.

Authors:  M F Donato; E Arosio; E Del Ninno; G Ronchi; P Lampertico; A Morabito; M R Balestrieri; M Colombo
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

2.  Associations of plasma aflatoxin B1-albumin adduct level with plasma selenium level and genetic polymorphisms of glutathione S-transferase M1 and T1.

Authors:  S Y Chen; C J Chen; W Y Tsai; H Ahsan; T Y Liu; J T Lin; R M Santella
Journal:  Nutr Cancer       Date:  2000       Impact factor: 2.900

3.  Association of hTcf-4 gene expression and mutation with clinicopathological characteristics of hepatocellular carcinoma.

Authors:  Ying Jiang; Xin-Da Zhou; Yin-Kun Liu; Xin Wu; Xiao-Wu Huang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 4.  COX-2 - a target for preventing hepatic carcinoma?

Authors:  Mohammad A Rahman; Hitoshi Kohno; Naofumi Nagasue
Journal:  Expert Opin Ther Targets       Date:  2002-08       Impact factor: 6.902

5.  Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci.

Authors:  Moritoshi Kinoshita; Masahiko Miyata
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

6.  Genetic alterations and oncogenic pathways in hepatocellular carcinoma.

Authors:  Laurence Lévy; Claire Angélique Renard; Yu Wei; Marie Annick Buendia
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

7.  Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells.

Authors:  Paul J Chiao; Ren Na; Jiangong Niu; Guido M Sclabas; Qianggang Dong; Steven A Curley
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

8.  Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice.

Authors:  Masayuki Nakau; Hiroyuki Miyoshi; Michael F Seldin; Masayuki Imamura; Masanobu Oshima; Makoto M Taketo
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

9.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.

Authors:  Lihua Ming; Snorri S Thorgeirsson; Mitchell H Gail; Peixin Lu; Curtis C Harris; Nengjin Wang; Yongfu Shao; Zhiyuan Wu; Guoting Liu; Xiaohong Wang; Zongtang Sun
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

10.  Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.

Authors:  Yu Wei; Jeanne Tran Van Nhieu; Sylvie Prigent; Petcharin Srivatanakul; Pierre Tiollais; Marie-Annick Buendia
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  10 in total

1.  MR diffusion-weighed imaging of rabbit liver.

Authors:  You-Hong Yuan; En-Hua Xiao; Zhong He; Jun Xiang; Ke-Li Tang; Rong-Hua Yan; Ke Jin; Zi-Wen Peng
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

2.  Family history influences the early onset of hepatocellular carcinoma.

Authors:  Chung-Hwa Park; Seung-Hee Jeong; Hyeon-Woo Yim; Jin Dong Kim; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

3.  The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.

Authors:  Manal M Hassan; Margret R Spitz; Melanie B Thomas; Steven A Curley; Yehuda Z Patt; Jean-Nicolas Vauthey; Katrina Y Glover; Ahmed Kaseb; Richard D Lozano; Adel S El-Deeb; Nga T Nguyen; Steven H Wei; Wenyaw Chan; James L Abbruzzese; Donghui Li
Journal:  J Hepatol       Date:  2008-10-16       Impact factor: 25.083

4.  Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis.

Authors:  Francesco Feo; Maddalena Frau; Rosa-Maria Pascale
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

5.  Differential expression of genes during aflatoxin B(1)-induced hepatocarcinogenesis in tree shrews.

Authors:  Yuan Li; Da-Fang Wan; Jian-Jia Su; Ji Cao; Chao Ou; Xiao-Kun Qiu; Ke-Chen Ban; Chun Yang; Liu-Liang Qin; Dan Luo; Hui-Fen Yue; Li-Sheng Zhang; Jian-Ren Gu
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

6.  HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Authors:  Ying Chen; Johnny Sze; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

7.  Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.

Authors:  Maria M Simile; Gavinella Latte; Maria I Demartis; Stefania Brozzetti; Diego F Calvisi; Alberto Porcu; Claudio F Feo; Maria A Seddaiu; Lucia Daino; Carmen Berasain; Maria L Tomasi; Matias A Avila; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2016-08-02

8.  Camptothecin-20(s)-O-[N-(3'α,12'α-dihydroxy-24'-carbonyl-5'β-cholan)]-lysine, a novel camptothecin analogue, induces apoptosis towards hepatocellular carcinoma SMMC-7721 cells.

Authors:  Qingyong Li; Wei Qiu; Qiaochu Zhu; Yuangang Zu; Xiaoqiu Deng; Tengfei Zhao; Chunfei Jiang; Li Zhang
Journal:  Molecules       Date:  2011-09-13       Impact factor: 4.411

Review 9.  Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Authors:  Rosa M Pascale; Maria M Simile; Graziella Peitta; Maria A Seddaiu; Francesco Feo; Diego F Calvisi
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

10.  Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma.

Authors:  Deke Jiang; Jiaen Deng; Changzheng Dong; Xiaopin Ma; Qianyi Xiao; Bin Zhou; Chou Yang; Lin Wei; Carly Conran; S Lilly Zheng; Irene Oi-Lin Ng; Long Yu; Jianfeng Xu; Pak C Sham; Xiaolong Qi; Jinlin Hou; Yuan Ji; Guangwen Cao; Miaoxin Li
Journal:  BMC Cancer       Date:  2020-05-11       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.